COG — Cambridge Cognition Holdings Share News
0.000.00%
Last trade - 00:00- £14.81m
- £14.46m
- £9.40m
Brief: Cambridge Cognition Says Monument Therapeutics Achieves Positive Phase I Results For Novel Schizophrenia Treatment
RCS - Cambridge Cognition - Monument Therapeutics Success in Phase I Results
Cambridge Cognition - Notice of AGM
Cambridge Cognition - Holding(s) in Company
Brief: Cambridge Cognition Holdings FY Revenue £10.3 Mln
Cambridge Cognition - Preliminary Unaudited Results
Cambridge Cognition - Notice of Results and Investor Presentation
Brief: Cambridge Cognition Secures 1 Mln Stg Contract For Phase 3 Trial
Cambridge Cognition - Contract Win
Cambridge Cognition - Holding(s) in Company
Brief: Cambridge Cognition Says Selected For Two Phase 3 Trials Combining Digital Cognitive And Voice Solutions
Cambridge Cognition - Contract Win
RCS - Cambridge Cognition - CANTAB® used for major global brain health study
Brief: Cambridge Cognition Holdings Proposes Digital Cognitive Assessment For CIAS Trials
RCS - Cambridge Cognition - Cambridge Cognition submits FDA Letter of Intent
Cambridge Cognition - Board Appointment
Brief: Cambridge Cognition Expands Partnership With Actinogen
Cambridge Cognition - Expanded partnership with Actinogen
RCS - Cambridge Cognition - CANTAB® success in Bristol Myers Squib research